Analysis and Validation of Critical Signatures and Immune Cell Infiltration Characteristics in Doxorubicin-Induced Cardiotoxicity by Integrating Bioinformatics and Machine Learning

References

• Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409–436. doi:10.3322/caac.21731
   PubMed Web of Science ®Google Scholar
• Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol. 2017;70(20):2536–2551. doi:10.1016/j.jacc.2017.09.1096
   PubMedGoogle Scholar
• Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med. 1981;305(3):139–153. doi:10.1056/nejm198107163050305
   PubMed Web of Science ®Google Scholar
• Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–2801. doi:10.1093/eurheartj/ehw211
   PubMed Web of Science ®Google Scholar
• Wallace KB, Sardao VA, Oliveira PJ. Mitochondrial determinants of doxorubicin-induced cardiomyopathy. Circ Res. 2020;126(7):926–941. doi:10.1161/CIRCRESAHA.119.314681
   PubMed Web of Science ®Google Scholar
• Ni C, Ma P, Wang R, et al. Doxorubicin-induced cardiotoxicity involves IFNgamma-mediated metabolic reprogramming in cardiomyocytes. J Pathol. 2019;247(3):320–332. doi:10.1002/path.5192
   PubMed Web of Science ®Google Scholar
• Brandao SR, Carvalho F, Amado F, Ferreira R, Costa VM. Insights on the molecular targets of cardiotoxicity induced by anticancer drugs: a systematic review based on proteomic findings. Metabolism. 2022;134:155250. doi:10.1016/j.metabol.2022.155250
   PubMed Web of Science ®Google Scholar
• Kong CY, Guo Z, Song P, et al. Underlying the mechanisms of doxorubicin-induced acute cardiotoxicity: oxidative stress and cell death. Int J Biol Sci. 2022;18(2):760–770. doi:10.7150/ijbs.65258
   PubMed Web of Science ®Google Scholar
• Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease. Nat Rev Immunol. 2018;18(12):733–744. doi:10.1038/s41577-018-0065-8
   PubMed Web of Science ®Google Scholar
• Sun K, Li YY, Jin J. A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair. Signal Transduct Target Ther. 2021;6(1):79. doi:10.1038/s41392-020-00455-6
   PubMed Web of Science ®Google Scholar
• Sawicki KT, Sala V, Prever L, et al. Preventing and treating anthracycline cardiotoxicity: new insights. Annu Rev Pharmacol Toxicol. 2021;61:309–332. doi:10.1146/annurev-pharmtox-030620-104842
   PubMed Web of Science ®Google Scholar
• Kawamura M, Miyagawa S, Fukushima S, et al. Enhanced survival of transplanted human induced pluripotent stem cell-derived cardiomyocytes by the combination of cell sheets with the pedicled omental flap technique in a porcine heart. Circulation. 2013;128(11 Suppl 1):S87–S94. doi:10.1161/circulationaha.112.000366
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Yamanaka S. iPS cells: a source of cardiac regeneration. J Mol Cell Cardiol. 2011;50(2):327–332. doi:10.1016/j.yjmcc.2010.10.026
   PubMed Web of Science ®Google Scholar
• Burridge PW, Li YF, Matsa E, et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med. 2016;22(5):547–556. doi:10.1038/nm.4087
   PubMed Web of Science ®Google Scholar
• Hsu WT, Huang CY, Yen CYT, Cheng AL, Hsieh PCH. The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling. Theranostics. 2018;8(12):3176–3188. doi:10.7150/thno.23207
   PubMed Web of Science ®Google Scholar
• Magdy T, Jouni M, Kuo HH, et al. Identification of drug transporter genomic variants and inhibitors that protect against doxorubicin-induced cardiotoxicity. Circulation. 2022;145(4):279–294. doi:10.1161/circulationaha.121.055801
   PubMed Web of Science ®Google Scholar
• Maillet A, Tan K, Chai X, et al. Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes. Sci Rep. 2016;6(25333). doi:10.1038/srep25333
   Google Scholar
• Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991–D995. doi:10.1093/nar/gks1193
   PubMed Web of Science ®Google Scholar
• Kattih B, Shirvani A, Klement P, et al. IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-A retrospective propensity score analysis. Leukemia. 2021;35(5):1301–1316. doi:10.1038/s41375-020-01043-x
   PubMed Web of Science ®Google Scholar
• Huang H, Christidi E, Shafaattalab S, et al. RARG S427L attenuates the DNA repair response to doxorubicin in induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Rep. 2022;17(4):756–765. doi:10.1016/j.stemcr.2022.03.002
   PubMed Web of Science ®Google Scholar
• Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28(6):882–883. doi:10.1093/bioinformatics/bts034
   PubMed Web of Science ®Google Scholar
• Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80. doi:10.1186/gb-2004-5-10-r80
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Breiman L. Random forests. Mach Learn. 2001;4:5–32.
   Google Scholar
• Tibshirani R. Regression shrinkage and selection via the lasso. J Royal Stat Soc Series B. 1996;58(1):267–288. doi:10.1111/j.2517-6161.1996.tb02080.x
   Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinf. 2008;9(559). doi:10.1186/1471-2105-9-559
   PubMedGoogle Scholar
• Kang J, Tang Q, He J, et al. RNAInter v4.0: RNA interactome repository with redefined confidence scoring system and improved accessibility. Nucleic Acids Res. 2022;50(D1):D326–D332. doi:10.1093/nar/gkab997
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu W, Zhang HM, et al. hTFtarget: a comprehensive database for regulations of human transcription factors and their targets. Genomics Proteomics Bioinf. 2020;18(2):120–128. doi:10.1016/j.gpb.2019.09.006
   PubMed Web of Science ®Google Scholar
• Tokar T, Pastrello C, Rossos AEM, et al. mirDIP 4.1-integrative database of human microRNA target predictions. Nucleic Acids Res. 2018;46(D1):D360–D370. doi:10.1093/nar/gkx1144
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.1239303
   PubMed Web of Science ®Google Scholar
• Tian C, Yang Y, Li B, et al. Doxorubicin-Induced cardiotoxicity may be alleviated by bone marrow mesenchymal stem cell-derived exosomal lncRNA via inhibiting inflammation. J Inflamm Res. 2022;15:4467–4486. doi:10.2147/jir.S358471
   PubMed Web of Science ®Google Scholar
• Sumneang N, Tanajak P, Oo TT. Toll-like receptor 4 inflammatory perspective on doxorubicin-induced cardiotoxicity. Molecules. 2023;28(11). doi:10.3390/molecules28114294
   PubMed Web of Science ®Google Scholar
• Bhagat A, Shrestha P, Kleinerman ES. The innate immune system in cardiovascular diseases and its role in doxorubicin-induced cardiotoxicity. Int J Mol Sci. 2022;23(23). doi:10.3390/ijms232314649
   Web of Science ®Google Scholar
• Pan JA, Tang Y, Yu JY, et al. miR-146a attenuates apoptosis and modulates autophagy by targeting TAF9b/P53 pathway in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2019;10(9):668. doi:10.1038/s41419-019-1901-x
   PubMedGoogle Scholar
• Pawan K, Singal DS, Iliskovic N. Doxorubicin-induced cardiomyopathy. New Engl J Med. 1998;339(13):900–905.
   PubMed Web of Science ®Google Scholar
• Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474–502. doi:10.1038/s41569-020-0348-1
   PubMed Web of Science ®Google Scholar
• Vandereyken K, Sifrim A, Thienpont B, Voet T. Methods and applications for single-cell and spatial multi-omics. Nat Rev Genet. 2023;24(8):494–515. doi:10.1038/s41576-023-00580-2
   PubMed Web of Science ®Google Scholar
• Barbulovic-Nad I, Lucente M, Sun Y, et al. Bio-microarray fabrication techniques--A review. Crit Rev Biotechnol. 2006;26(4):237–259. doi:10.1080/07388550600978358
   PubMed Web of Science ®Google Scholar
• Miyazaki S, Yamano H, Motooka D, et al. Zfp296 knockout enhances chromatin accessibility and induces a unique state of pluripotency in embryonic stem cells. Commun Biol. 2023;6(1):771. doi:10.1038/s42003-023-05148-8
   PubMed Web of Science ®Google Scholar
• Kloet SL, Karemaker ID, van Voorthuijsen L, et al. NuRD-interacting protein ZFP296 regulates genome-wide NuRD localization and differentiation of mouse embryonic stem cells. Nat Commun. 2018;9(1):4588. doi:10.1038/s41467-018-07063-7
   PubMedGoogle Scholar
• Kjaer IM, Kahns S, Timm S, et al. Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA. Sci Rep. 2023;13(1):8419. doi:10.1038/s41598-023-35362-7
   PubMed Web of Science ®Google Scholar
• Matsuura T, Miyazaki S, Miyazaki T, Tashiro F, Miyazaki JI. Zfp296 negatively regulates H3K9 methylation in embryonic development as a component of heterochromatin. Sci Rep. 2017;7(1):12462. doi:10.1038/s41598-017-12772-y
   PubMedGoogle Scholar
• Fujii Y, Kakegawa M, Koide H, Akagi T, Yokota T. Zfp296 is a novel Klf4-interacting protein and functions as a negative regulator. Biochem Biophys Res Commun. 2013;441(2):411–417. doi:10.1016/j.bbrc.2013.10.073
   PubMed Web of Science ®Google Scholar
• Gliddon HD, Kaforou M, Alikian M, et al. Identification of reduced host transcriptomic signatures for tuberculosis disease and digital PCR-based validation and quantification. Front Immunol. 2021;12(637164). doi:10.3389/fimmu.2021.637164
   PubMedGoogle Scholar
• Gulberti S, Jacquinet JC, Chabel M, et al. Chondroitin sulfate N-acetylgalactosaminyltransferase-1 (CSGalNAcT-1) involved in chondroitin sulfate initiation: impact of sulfation on activity and specificity. Glycobiology. 2012;22(4):561–571. doi:10.1093/glycob/cwr172
   PubMed Web of Science ®Google Scholar
• Agnelli L, Forcato M, Ferrari F, et al. The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res. 2011;17(23):7402–7412. doi:10.1158/1078-0432.CCR-11-0596
   PubMed Web of Science ®Google Scholar
• Kruk D, Yeung ACY, Faiz A, et al. Gene expression profiles in mesenchymal stromal cells from bone marrow, adipose tissue and lung tissue of COPD patients and controls. Respir Res. 2023;24(1):22. doi:10.1186/s12931-023-02314-8
   PubMed Web of Science ®Google Scholar
• Yang J, Shen M, Wen H, et al. Recent advance in delivery system and tissue engineering applications of chondroitin sulfate. Carbohydr Polym. 2020;230(115650). doi:10.1016/j.carbpol.2019.115650
   Google Scholar
• Zhao RR, Ackers-Johnson M, Stenzig J, et al. Targeting chondroitin sulfate glycosaminoglycans to treat cardiac fibrosis in pathological remodeling. Circulation. 2018;137(23):2497–2513. doi:10.1161/circulationaha.117.030353
   PubMed Web of Science ®Google Scholar
• Cen C, Chen J, Lin L, et al. Fancb deficiency causes premature ovarian insufficiency in mice†. Biol Reprod. 2022;107(3):790–799. doi:10.1093/biolre/ioac103
   PubMed Web of Science ®Google Scholar
• Du W, Amarachintha S, Erden O, et al. Fancb deficiency impairs hematopoietic stem cell function. Sci Rep. 2015;5(18127). doi:10.1038/srep18127
   Google Scholar
• D’Andrea MGA. Fanconi anemia and DNA repair. Human Molecular Genetics. 2001;10(20):2253–2259.
   PubMed Web of Science ®Google Scholar
• Chung YH, Qian Q, Huang HY, et al. The nuclear function of IL-33 in desensitization to DNA damaging agent and change of glioma nuclear structure. Front Cell Neurosci. 2021;15(713336). doi:10.3389/fncel.2021.713336
   Google Scholar
• Dong Y, Xu S, Liu J, et al. Non-coding RNA-linked epigenetic regulation in cardiac hypertrophy. Int J Biol Sci. 2018;14(9):1133–1141. doi:10.7150/ijbs.26215
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi:10.1016/s0092-8674(04)00045-5
   PubMed Web of Science ®Google Scholar
• Fa HG, Chang WG, Zhang XJ, Xiao DD, Wang JX. Noncoding RNAs in doxorubicin-induced cardiotoxicity and their potential as biomarkers and therapeutic targets. Acta Pharmacol Sin. 2021;42(4):499–507. doi:10.1038/s41401-020-0471-x
   PubMed Web of Science ®Google Scholar
• Sano S, Wang Y, Ogawa H, et al. TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-mediated cytotoxic response. JCI Insight. 2021;6(13). doi:10.1172/jci.insight.146076
   Web of Science ®Google Scholar
• Bhagat A, Shrestha P, Jeyabal P, et al. Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase. Front Oncol. 2022;12(947604). doi:10.3389/fonc.2022.947604
   Google Scholar
• Kaczmarek A, Krysko O, Heyndrickx L, et al. TNF/TNF-R1 pathway is involved in doxorubicin-induced acute sterile inflammation. Cell Death Dis. 2013;4(12):e961. doi:10.1038/cddis.2013.496
   PubMedGoogle Scholar
• Krysko DV, Kaczmarek A, Krysko O, et al. TLR-2 and TLR-9 are sensors of apoptosis in a mouse model of doxorubicin-induced acute inflammation. Cell Death Differ. 2011;18(8):1316–1325. doi:10.1038/cdd.2011.4
   PubMed Web of Science ®Google Scholar
• Obata Y, Ishimori N, Saito A, et al. Activation of invariant natural killer T cells by alpha-galactosylceramide ameliorates doxorubicin-induced cardiotoxicity in mice. Eur J Prev Cardiol. 2020;27(19):2358–2361. doi:10.1177/2047487319901208
   PubMed Web of Science ®Google Scholar
• Ye J, Huang Y, Que B, et al. Interleukin-12p35 knock out aggravates doxorubicin-induced cardiac injury and dysfunction by aggravating the inflammatory response, oxidative stress, apoptosis and autophagy in mice. EBioMedicine. 2018;35:29–39. doi:10.1016/j.ebiom.2018.06.009
   PubMed Web of Science ®Google Scholar
• Zhang H, Xu A, Sun X, et al. Self-maintenance of cardiac resident reparative macrophages attenuates doxorubicin-induced cardiomyopathy through the SR-A1-c-Myc axis. Circ Res. 2020;127(5):610–627. doi:10.1161/circresaha.119.316428
   PubMed Web of Science ®Google Scholar
• Inada R, Miyamoto K, Tanaka N, et al. Chondroitin sulfate N-acetylgalactosyltransferase-1 knockout shows milder phenotype in experimental autoimmune encephalomyelitis than in wild type. Glycobiology. 2021;31(3):260–265. doi:10.1093/glycob/cwaa072
   PubMed Web of Science ®Google Scholar